Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin-12 in AIDS-Associated Kaposi's Sarcoma
NCT00019188Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 1997
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of recombinant interleukin-12 in Kaposi's sarcoma (KS), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 6 months, Antitumor activity at 6 months and 2 more. Started Jan 1997; status: completed.
02
Drugs
recombinant interleukin-12
03
Conditions
Kaposi's sarcoma (KS)
Beyond the preview
Go deeper on NCT00019188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00019188.